Service is in preparation Official β release coming soon. Some features are still being adjusted.

Investical Earnings & investing calendar Earnings & investing calendar
/
2395TSE Prime

SHIN NIPPON BIOMEDICAL LABORATORIES,LTD.

新日本科学 Yahoo Finance

Recent & upcoming events

Aug 5
Earnings 2:00
Q1 earnings announcement (scheduled)
Add to Google Calendar
Jun 25
Shareholder meeting Time TBD
Shareholders' meeting
Add to Google Calendar
May 11
Earnings 2:00
FY earnings announcement (scheduled)
Add to Google Calendar
Sep 27
Est.
Dividend Time TBD
Last day with rights (interim)
Add to Google Calendar
Sep 28
Est.
Ex-dividend Time TBD
Ex-rights date (interim)
Add to Google Calendar
Oct 28
Est.
Earnings 2:00 approx.
Q2 earnings
Add to Google Calendar
2027
Jan 27
Est.
Earnings 1:00 approx.
Q3 earnings
Add to Google Calendar
Mar 28
Est.
Dividend Time TBD
Last day with rights (year-end)
Add to Google Calendar
Mar 29
Est.
Ex-dividend Time TBD
Ex-rights date (year-end)
Add to Google Calendar
Apr 21
Est.
Earnings 2:00 approx.
Full-year earnings
Add to Google Calendar
Jul 14
Est.
Earnings 2:00 approx.
Q1 earnings
Add to Google Calendar

KPI highlights

FY26
Revenue ¥32.52B YoY +0.3%
Operating income ¥2.65B margin 8.2%
Net income ¥4.57B YoY -7.3%
EPS ¥110 YoY -7.3%
P/E —
ROE 11.0% Equity ratio 41% Typical equity ratios vary a lot by industry. Banks, brokerages, and other financial companies tend to run lower ratios because leverage (using other people's capital) is core to their business model — a low ratio there isn't a sign of financial weakness.

Company guidance

FY2027/03 Company-issued full-year guidance (from earnings report) / %=vs prior FY
Revenue ¥38.00B +16.8%
Operating income ¥3.00B +13.0%
Net income ¥3.50B -23.4%
EPS ¥84 -23.4%

Quarterly fundamentals

Income & cash flow
Quarter FY23 Q2FY23 Q3FY23 Q4FY24 Q1FY24 Q2FY25 Q2
Revenue ¥5.80B¥6.08B¥6.10B¥8.47B——
Operating income ¥1.23B¥1.12B¥186M¥1.63B——
Net income ¥1.38B¥1.59B¥831M¥1.71B——
Operating CF ——————

Ownership over time

Share of total shares outstanding (disclosed major holdings + undisclosed)（2022–2026）

事業法人 41.5%国内機関 13.2%海外機関 3.7%個人 7.8%その他 3.5%未開示 30.3%20222023202420252026
事業法人国内機関海外機関個人その他未開示・浮動株

「国内機関」は信託銀行の名義口座（年金・パッシブ・一部海外資本を含む）を集計し、実質保有者へは分解していません。分類は開示名称からの推定です。

Top shareholders — rank & share

Nagata and Company 40.3%Nagata and Company株式会社日本マスタートラスト信託銀行株式会社 7%日本マスタートラスト信託銀行株式会社（信託口）株式会社日本カストディ銀行（信託口） 5.2%株式会社日本カストディ銀行（信託口）永田　貴久 4.4%永田　貴久一般社団法人メディポリス医学研究所 3.5%一般社団法人メディポリス医学研究所梅原 理恵 2.5%梅原 理恵20222023202420252026

Top shareholders — actual figures (as of 2026)

Holder Shares held Ratio Source
Nagata and Company株式会社 16,788,000 40.3% Yuho (EDINET)
日本マスタートラスト信託銀行株式会社（信託口） 2,920,000 7.0% Yuho (EDINET)
株式会社日本カストディ銀行（信託口） 2,175,000 5.2% Yuho (EDINET)
永田 貴久 1,840,000 4.4% Yuho (EDINET)
BNP PARIBAS LUXEMBOURG／2S／JASDEC／FIM／LUXEMBOURGFUNDS／UCITS ASSETS 1,550,000 3.7% Yuho (EDINET)
一般社団法人メディポリス医学研究所 1,474,000 3.5% Yuho (EDINET)
梅原 理恵 1,024,000 2.5% Yuho (EDINET)
野村證券株式会社 472,000 1.1% Yuho (EDINET)
モルガン・スタンレーMUFG証券株式会社 398,000 1.0% Yuho (EDINET)
新日本科学従業員持株会 372,000 0.9% Yuho (EDINET)

Source：EDINET（大株主の状況）　Classification inferred from disclosed names

F-Score (Piotroski)

4/9

Checks financial health against 9 criteria and shows how many are met as a fraction (more ✓ marks is healthier). Items with no data are shown as “—” — they're simply excluded from judgment, not counted against the score.

✓ Positive ROA ROA 4.3%
✓ Positive operating cash flow ¥8.33B
✗ ROA improved YoY 5.3% → 4.3%
✓ Operating CF exceeds net income (accrual quality) OCF ¥8.33B / net income ¥4.57B
✗ Equity ratio improved* Substitute for the original “decrease in long-term debt” 43.3% → 41.0%
✗ Current ratio improved 1.13× → 1.09×
✓ No dilution (shares outstanding did not increase) 41,632,400 → 41,632,400
✗ Gross margin improved 52.3% → 49.9%
✗ Asset turnover improved 0.35× → 0.31×

This score is reference information based on our own financial metrics. It is NOT a credit rating issued by a credit rating agency under Article 66-27 of the Financial Instruments and Exchange Act, and is NOT investment advice or a recommendation. Make investment decisions at your own responsibility.

Fact checklist

FY26
Equity ratio 41.0%
Current ratio 1.1×
Years of positive operating CF 9 of last 10 yrs
Payout ratio 82%
Latest fiscal year result Profit (net income ¥4.57B)

Performance history

Last 10 years
0億円81億円163億円244億円325億円 FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26

Income & assets

Unit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
Revenue 172166157146151177251265324325
Operating income -17.9-6.978.3022.325.342.052.541.629.926.5
Ordinary income -21.1-8.1316.131.236.570.891.970.264.558.3
Net income -9.16-35.619.525.536.671.360.655.349.245.7
Total assets 5635765433903703935727639241,051
Equity 225262285164158197264342401435

Indicators & cash flow

Unit: ¥100M
Item FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26
EPS ¥-22¥-85¥47¥61¥88¥171¥146¥133¥118¥110
ROE ——7.1%11.4%22.9%40.4%26.5%18.3%13.3%11.0%
Operating CF -8.5013.428.930.247.559.540.021.170.483.3
Investing CF -3.148.384.35-14.6-2.69-42.7-59.3-69.1-117-67.9
Financing CF 38.2-42.2-35.0-14.5-24.7-49.162.753.259.145.1
FCF -11.621.833.315.644.816.8-19.3-48.0-46.615.4

A “—” means data wasn't available for that period — it's not a display error or an unusual value.

Source: EDINET (Annual Securities Report) (fetched 2026-08-29) *Some metrics supplemented from additional sources

Key financial metrics

3-year revenue growth ✓

Sector positioning

Relative standing within the sector
Is this information incorrect?

Data provided by Twelve Data